Overview

* NextCure ( NXTC ) Q3 net loss decreases compared to same period last year

* Company advances ADC programs with U.S. enrollment and FDA clearance for protocol amendment

* Financial resources expected to fund operations into mid-2026

Outlook

* NextCure's ( NXTC ) current financial resources expected to last into mid-2026

Result Drivers

* ADC PROGRAM ADVANCEMENT - NextCure ( NXTC ) progressed ADC programs with U.S. enrollment for SIM0505 and FDA clearance for LNCB74 protocol amendment

* Research and development expenses were $6.1 million for the three months ended September 30, 2025, as compared to $8.8 million for the three months ended September 30, 2024.

* FINANCIAL RESOURCE MANAGEMENT - Cash reserves decreased due to operational funding and license fees, but expected to fund operations into mid-2026

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$8.62

Income mln

Q3 Basic -$3.22

EPS

Q3 -$8.95

Income mln

from

Operatio

ns

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for NextCure Inc ( NXTC ) is $17.50, about 44.9% above its November 4 closing price of $9.64

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)